Abstract
Purpose :
Landmark studies have demonstrated the efficacy of Anti-VEGFand ozurdex in treating cystoid macular oedema ( CMO) secondery to branch retinal vein occlusion( BRVO) under highly controlled circumstances. This retrospective, observational clinical study examines and compares aflibercept, ozurdex, ranibizumab with macular argon laser treatment outcome to idealized outcomes of the landmark studies.
Methods :
Between June 2013 and November 2018, two hunderds and fifty eight eyes with cystoid macular oedema (CMO) secondary to BRVO were treated with aflibercept, ozurdex and ranibizumab with Argon focal laser in the ophthalmic department of North Middlesex University Hospital at monthly intervals until maximum visual acuity and OCT parameters were realized. All patients treated in the unit during this period were analyzed retrospectively for the following outcomes: improve functional vision, total visual gain, decrease in OCT-measured central retinal thickness (CRT), proportion achieving dry OCT, progression neovascularisation, Data was retrospectively collected and compared.
Results :
Overal results shows significant improvement in visual acuity (VA) with anti-VEGF treatment and ozurdex compared to non- treated group. Fifty nine percent who receieved aflibercept treatment alone acheieved dry macula after five monthly injections. Sixty three percent who receievd focal argon macular laser followed by ranibizumab acheieved dry macula after five monthly injections.
Conclusions :
In a real world setting, treatment of cystoid macular oedema( CMO) secondary to BRVO either by ozurdex, aflibercept or ranibizumab with focal macular argon laser compares favourably to the landmark clinical trials with idealized circumstances. Although visual acuity parameters did not improve to the same degree as in the clinical trials, anatomical parameters did.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.